LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Diagnostic Products Detect Prostate Cancer

By LabMedica International staff writers
Posted on 19 Jun 2017
Print article
Image: The UrNCollect device is designed for use with the SelectMDx in vitro diagnostic (IVD) PCR test kit for prostate cancer (Photo courtesy of MDxHealth).
Image: The UrNCollect device is designed for use with the SelectMDx in vitro diagnostic (IVD) PCR test kit for prostate cancer (Photo courtesy of MDxHealth).
A novel sample collection device was designed to support a urine-based non-invasive "liquid biopsy" molecular diagnostic test that determines the risk for developing high-grade prostate cancer.

The biomedical company MDxHealth SA (Herstal, Belgium) has announced the European launch of its CE-marked UrNCollect device for use with the SelectMDx in vitro diagnostic (IVD) PCR test kit for prostate cancer.

UrNCollect is a user-friendly device that enables the hygienic and standardized collection of the first 16 milliliters of the urine stream and reduces laboratory errors by automating preservative mixing without additional handling or pipetting.

The SelectMDx PCR kit enables diagnostic laboratories with manual and automated RNA extraction and PCR platforms to perform the liquid biopsy test in their own facility. Laboratories that are not equipped to use the IVD PCR kit can have samples processed at MDxHealth’s state-of-the-art ISO-certified diagnostic facilities in Nijmegen, the Netherlands or Irvine, California, USA.

“Many of our current customers are eager to start using the IVD PCR kit so they can run the SelectMDx for prostate cancer test in their own labs,” said Dr. Jan Groen, CEO of MDxHealth. “It is well-timed that our UrNCollect device is launching as a complement to the SelectMDx IVD PCR kit because pilot studies demonstrated that patients and physicians found the device easier to use than traditional urine collection tubes.”

A technical validation study that assessed and confirmed the robustness, reproducibility, and interlaboratory performance of SelectMDx was published in the May 11, 2017, issue of the journal Translational Medicine Communications.

Related Links:
MDxHealth

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more